AuntMinnie.com Highlighted Forums (Newer)

Jan 15, 2021

2018 04 11 22 20 4107 Clash Of The Cases

648389,Struggling during residency 648681,Can AI spot breast cancer years before radiologists? 648274,Partnership track dilemma 648125,Private practices in NYC 648677,Advice on starting part-time radiology chart review job

Football Players Scrimmage

Adding AI to MRI improves return to play classification frameworks

December 10, 2025

Runner Street Thumbnail Adobe Augustas Cetkauskas

Marathon training does not have long-term negative effects on heart

December 10, 2025

Scans in a 73-year-old man with biochemically recurrent prostate cancer (prostate-specific antigen level of 0.5 ng/mL) who underwent PET/CT with 9.4 mCi of F-18 piflufolastat and a second PET/CT examination with 8.1 mCi of copper 61-NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid)–prostate-specific membrane antigen for imaging and therapy (Cu-61 PSMA I&T) 24 days apart, with no intervening therapy. Maximum intensity projection (MIP) images obtained (A) 1 hour after F-18 piflufolastat administration and (B) 1, (C) 2, and (D) 4 hours after Cu-61 PSMA I&T administration are shown. Physiologic uptake is seen in the lacrimal glands, salivary glands, liver, spleen, kidneys, ureters, and bladder. Pathologic uptake in pelvic nodal metastases is labeled with arrows. The F-18 piflufolastat PET/CT MIP image reveals two avid pelvic nodal metastases (arrows). Cu-61 PSMA I&T PET/CT scans demonstrate three avid pelvic nodal metastases on 1-hour and 2-hour images (arrows); five avid pelvic nodal metastases were suspected on the 4-hour image (arrows).

Phase I trial reveals the potential of a new PSMA-PET tracer

December 9, 2025

Images depict a 50-year-old woman with a lesion detected during screening ultrasound. (A) Transverse and (B) longitudinal images reveal a 0.5-cm hypoechoic lesion (arrow) in the left breast. (C) Transverse color Doppler ultrasound image does not show an increase in vascularity. Two readers classified the lesion as a mass, whereas two others categorized it as a nonmass lesion, leading to its designation as a controversial nonmass lesion. Ultrasound-guided core needle biopsy and subsequent pathologic examination confirmed a nonproliferative breast change.

Radiologists can designate nonmass lesions on breast ultrasound

December 9, 2025

Adding AI to MRI improves return to play classification frameworks

By Kate Madden Yee

Predicting when athletes can safely return to play after an injury is key.

December 10, 2025

Football Players Scrimmage

Marathon training does not have long-term negative effects on heart

By Amerigo Allegretto

Echocardiography shows that endurance training by marathon runners does not have long-term negative effects on the heart.

December 10, 2025

Runner Street Thumbnail Adobe Augustas Cetkauskas

Phase I trial reveals the potential of a new PSMA-PET tracer

The radiotracer detected more lesions in men with metastatic disease than F-18 piflufolastat.

December 9, 2025

Scans in a 73-year-old man with biochemically recurrent prostate cancer (prostate-specific antigen level of 0.5 ng/mL) who underwent PET/CT with 9.4 mCi of F-18 piflufolastat and a second PET/CT examination with 8.1 mCi of copper 61-NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid)–prostate-specific membrane antigen for imaging and therapy (Cu-61 PSMA I&T) 24 days apart, with no intervening therapy. Maximum intensity projection (MIP) images obtained (A) 1 hour after F-18 piflufolastat administration and (B) 1, (C) 2, and (D) 4 hours after Cu-61 PSMA I&T administration are shown. Physiologic uptake is seen in the lacrimal glands, salivary glands, liver, spleen, kidneys, ureters, and bladder. Pathologic uptake in pelvic nodal metastases is labeled with arrows. The F-18 piflufolastat PET/CT MIP image reveals two avid pelvic nodal metastases (arrows). Cu-61 PSMA I&T PET/CT scans demonstrate three avid pelvic nodal metastases on 1-hour and 2-hour images (arrows); five avid pelvic nodal metastases were suspected on the 4-hour image (arrows).

Radiologists can designate nonmass lesions on breast ultrasound

By Amerigo Allegretto

Breast radiologists achieved moderate to substantial interreader agreement for classifying nonmass lesions on ultrasound.

December 9, 2025

Images depict a 50-year-old woman with a lesion detected during screening ultrasound. (A) Transverse and (B) longitudinal images reveal a 0.5-cm hypoechoic lesion (arrow) in the left breast. (C) Transverse color Doppler ultrasound image does not show an increase in vascularity. Two readers classified the lesion as a mass, whereas two others categorized it as a nonmass lesion, leading to its designation as a controversial nonmass lesion. Ultrasound-guided core needle biopsy and subsequent pathologic examination confirmed a nonproliferative breast change.

Long COVID's neurological effects persist

By Kate Madden Yee

Long COVID is typically defined as persistent symptoms beyond four weeks from onset of the illness.

December 9, 2025

MRI proves effective for tracking results of obesity interventions

By Kate Madden Yee

MRI is a powerful tool to monitor skeletal muscle adaptations during lifestyle interventions for obesity, researchers noted.

December 8, 2025

TVR-PET/CT shows promise in primary hyperparathyroidism

Gallium-68 trivehexin PET/CT was superior for identifying lesions over technetium-99m sestamibi SPECT.

December 8, 2025

ACR talks BI-RADS version 2025 with AuntMinnie

By Amerigo Allegretto

ACR members discussed the need to release the latest version of BI-RADS and what changes breast radiologists can expect.

December 8, 2025

ACR's Ted Burnes talks advocacy in radiology with AuntMinnie

By Amerigo Allegretto

Ted Burnes from the American College of Radiology spoke with AuntMinnie on achievements in advocacy and what 2026 may bring.

December 8, 2025

Screenshot (91)

PiB-PET/CT detects subtypes in cardiac amyloidosis

PiB-PET/CT shows strong promise as a next-generation diagnostic tool for cardiac amyloidosis.

December 5, 2025

HPI: 13.5B mL of contrast media administered from 2011 to 2024

By Kate Madden Yee

The findings are sobering, as contrast use contributes to environmental pollution.

December 5, 2025

Contrast Injector

AI ultrasound tool could reduce unnecessary biopsies by 60%

By Amerigo Allegretto

An AI tool could help reduce unnecessary breast biopsies, but should be used in conjunction with radiologist decision-making.

December 5, 2025

2025 12 05 Ai Decision Support Tool Ultrasound Thumbnail

Page 1 of 190